Expression and purification of the recombinant diphtheria fusion toxin DT388IL3 for phase I clinical trials

Protein Expression and Purification

Volumn 33, Issue 1, 2004, Pages 123-133

  Urieto, Jeffrey O ^a   Liu, TieFu ^a   Black, Jennifer H ^a   Cohen, Kimberley A ^a   Hall, Philip D ^b   Willingham, Mark C ^a   Pennell, Lewis K ^c   Hogge, Donna E ^d   Kreitman, Robert J ^e   Frankel, Arthur E ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

^d BRITISH COLUMBIA CANCER AGENCY   (Canada)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Diphtheria toxin; Interleukin 3; Monkeys

Indexed keywords

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; LIMULUS; MACACA FASCICULARIS;

EID: 9144264243     PISSN: 10465928     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pep.2003.09.003     Document Type: Article

References (29)

1. A. Jemal, T. Murray, A. Samuels, A. Ghaffor, E. Ward, M.J. Thun, Cancer statistics, 2003, CA Cancer J. Clin. 53 (2003) 5-26.
2. J.M. Bennett, M.L. Young, J.W. Andersen, P.A. Cassileth, M.S. Tallman, E. Paietta, P.M. Wiernik, J.M. Rowe, Long-term survival in acute myeloid leukemia: the Eastern Cooperative Oncology Group Experience, Cancer 80 (Suppl. 11) (1997) 2205-2209.
3. N. Vey, M. Keating, F. Giles, J. Cortes, M. Beran, E. Estey, Effect of complete remission on survival of patients with acute myelogenous leukemia receiving first salvage therapy, Blood 93 (1999) 3149-3150.
4. J.J. Clark, F.O. Smith, R.J. Arceci, Update in childhood acute myeloid leukemia: recent developments in the molecular basis of disease and novel therapies, Curr. Opin. Hematol. 10 (2003) 31-39.
5. R.A. Larson, Is modulation of multidrug resistance a viable strategy for acute myeloid leukemia?, Leukemia 17 (2003) 488-491.
6. M. Andreef, M. Konopleva, Mechanisms of drug resistance in AML, Cancer Treat. Res. 112 (2002) 237-262.
7. A. Sauerbrey, F. Zintl, J. Hermann, M. Volm, Multiple resistance mechanisms in acute nonlymphoblastic leukemia (ANLL), Anti-cancer Res. 18 (1998) 1231-1236.
8. S. Choe, M.J. Bennett, G.f. Fujii, P.M.G. Curmi, K.A. Kantardjieff, R.J. Collier, D. Eisenberg, The crystal structure of diphtheria toxin, Nature 357 (1992) 216-222.
9. J.S. Brooke, J.H. Cha, Molecular characterization of key diphtheria toxin: receptor interactions, Biochem. Biophys. Res. Commun. 275 (2000) 374-381.
10. R. Ratts, H. Zeng, E.A. Berg, C. Blue, M.E. McComb, C.E. Costello, J.C. vanderSpek, J.R. Murphy, The cytosolic entry of diphtheria toxin catalytic domain requires the host cell cytosolic translocation factor complex, J. Cell Biol. 160 (2003) 1139-1150.
11. R.J. Collier, Understanding the mode of action of diphtheria toxin: a perspective on progress during the 20th century, Toxicon 39 (2001) 1793-1803.
12. J.C. vanderSpek, J.R. Murphy, Fusion protein toxins based on diphtheria toxin: selective targeting of growth factor receptors of eukaryotic cells, Methods Enzymol. 327 (2000) 239-249.
13. A.E. Frankel, J. Ramage, A. Latimer, T. Feely, S. Delatte, P. Hall, E. Tagge, R. Kreitman, M. Willingham, High level synthesis and maximal purification of the recombinant diphtheria fusion toxin DTGM for phase I clinical trials, Protein Express. Purif. 16 (1999) 190-201.
14. 388GMCSF) for refractory or relapsed acute myeloid leukemia, Clin. Cancer Res. 8 (2002) 1004-1013.
15. A. Nitsche, I. Junghahn, S. Thulke, J. Aumann, A. Radonic, I. Fichtner, W. Siegert, Interleukin-3 promotes proliferation and differentiation of human hematopoietic stem cells but reduces their repopulation potential in NOD/SCID mice, Stem Cells 21 (2003) 236-244.
16. F. Chang, L.S. Steelman, J.T. Lee, J.G. Shelton, P.M. Navolanic, W.L. Blalock, R.A. Franklin, J.A. McCubrey, Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention, Leukemia 17 (2003) 1263-1293.
17. U. Testa, R. Riccioni, S. Militi, E. Coccia, E. Stellacci, P. Samoggia, R. Lataglia, G. Mariani, A. Rossini, A. Battistini, F. Lo-Coco, C. Peschle, Elevated expression of IL-3Ralpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity and poor prognosis, Blood 100 (2002) 2980-2988.
18. C.T. Jordan, D. Upchurch, S.J. Szilvassy, M.L. Guzman, D.S. Howard, A.L. Pettigrew, T. Meyerrose, R. Rossi, B. Grimes, D.A. Rizzieri, S.M. Luger, G.L. Phillips, The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells, Leukemia 14 (2000) 1777-1784.
19. A.E. Frankel, J. Ramage, M. Kiser, R. Alexander, G. Kucera, M.S. Miller, Characterization of diphtheria fusion proteins targeted to the human interleukin-3 receptor, Protein Eng. 13 (2000) 575-581.
20. A.E. Frankel, J.A. McCubrey, M.S. Miller, S. Delatte, J. Ramage, M. Kiser, G.L. Kucera, R.L. Alexander, M. Beran, E.P. Tagge, R.J. Kreitman, D.E. Hogge, Diphtheria toxin fused to human interleukin-3 is toxic to blasts from patients with myeloid leukemias, Leukemia 14 (2000) 576-585.
21. R.L. Alexander, J. Ramage, G.L. Kucera, M.A. Caliguiri, A.E. Frankel, High affinity interleukin-3 receptor expression on blasts from patients with acute myelogenous leukemia correlates with cytotoxicity of a diphtheria toxin/IL-3 fusion protein, Leukoc. Res. 25 (2001) 875-881.
22. R.L. Alexander, G.L. Kucera, B. Klein, A.E. Frankel, In vitro interleukin-3 binding to leukemia cells predicts cytotoxicity of a diphtheria toxin/IL-3 fusion protein, Bioconjug. Chem. 11 (2000) 564-568.
23. 388IL3) prolongs disease-free survival of leukemic immunocompromised mice, Leukemia 17 (2003) 155-159.
24. M. Feuring-Buske, A.E. Frankel, R.L. Alexander, B. Gerhard, D.E. Hogge, A diphtheria toxin-interleukin 3 fusion protein is cytotoxic to primitive acute myeloid leukemia progenitors but spares normal progenitors, Cancer Res. 62 (2002) 1730-1736.
25. R. Wallin, E.N. Culp, D.B. Coleman, S.R. Goodman, A structural model of human erythrocyte band 2.1: alignment of chemical and functional domains, Proc. Natl. Acad. Sci. USA 81 (1984) 4095-4100.
26. G.L. Ellman, Tissue sulfhydryl groups, Arch. Biochem. Biophys. 82 (1959) 70-71.
27. P. Matsudaira, in: A Practical Guide to Protein and Peptide Purification for Microsequencing, second ed., Academic Press, San Diego, 1993, p. 55.
28. M. Kiser, J.A. McCubrey, L.S. Steelman, J.G. Shelton, J. Ramage, R.L. Alexander, G.L. Kucera, M. Pettenati, M.C. Willingham, M.S. Miller, A.E. Frankel, Oncogene-dependent engraftment of human myeloid leukemia cells in immunosuppressed mice, Leukemia 15 (2001) 814-818.
29. B.K. Klein, J.J. Shieh, E. Grabbe, X. Li, J.K. Welply, J.P. McKearn, Receptor binding kinetics of human IL-3 variants with altered proliferative activity, Biochem. Biophys. Res. Commun. 288 (2001) 1244-1249.